A host of new drugs and procedures entered the ophthalmic sphere in the past year with the FDA approving treatments for application in subspecialty areas of glaucoma, retina/vitreous, cornea/external disease, refractive surgery and cataract surgery.
Here are 10 of the most-read FDA approvals on Healio.com/OSN in 2018:
 
FDA approves Oxervate, the first drug to treat neurotrophic keratitis
Oxervate, cenegermin, developed by Dompé farmaceutici SpA, is the first FDA approved drug for the rare disease, which can cause loss of corneal sensation and impair corneal health. Read more.
 

Full Story →

A host of new drugs and procedures entered the ophthalmic sphere in the past year with the FDA approving treatments for application in subspecialty areas of glaucoma, retina/vitreous, cornea/external disease, refractive surgery and cataract surgery.
Here are 10 of the most-read FDA approvals on Healio.com/OSN in 2018:
 
FDA approves Oxervate, the first drug to treat neurotrophic keratitis
Oxervate, cenegermin, developed by Dompé farmaceutici SpA, is the first FDA approved drug for the rare disease, which can cause loss of corneal sensation and impair corneal health. Read more.
 

Full Story →